Bisphosphonates and oral surgery

Oral Surgery

Volumn 2, Issue 2, 2009, Pages 56-63

  Oliver, R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bone; Complication; Dento alveolar; Mandible; Maxilla; Wound healing

Indexed keywords

EID: 84867400521     PISSN: 17522471     EISSN: 1752248X     Source Type: Journal    
DOI: 10.1111/j.1752-248X.2009.01050.x     Document Type: Review

References (73)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
2. Vance MA. Osteonecrosis of the jaw and bisphosphonates: a comparison with white phosphorus, radium, and osteopetrosis. Clin Toxicol 2007;45:753-62.
3. Marx RE. Oral and Intravenous Bisphosphonate- Induced Osteonecrosis of the Jaws. History, Etiology, Prevention, and Treatment. Illinois: Quintessence Publishing Co, 2007.
4. Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 2007;79:69-71.
5. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-47.
6. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.
7. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009;67:2-12.
8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61: 1115-17.
9. Adam Z, Kozumplikova M, Pour L, Machalka M. Osteonecrosis of the jaw in the course of multiple myeloma treatment and bisphosphonate administration. Vnitr Lek 2006;52:176-80.
10. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport Aet al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.
11. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006;42:327-9.
12. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.
13. Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Perez A, Sebastian-Lopez C. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Med Oral Patol Oral Cir Bucal 2006;11:E76-9.
14. Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, PereiraCMet al. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis 2005;11:365-9.
15. Pongchaiyakul C, Auraiwan K, Kotruchin P, Kularbkaew C. Bisphosphonate-related osteonecrosis of the jaws (ONJ): a report of two cases. J Med Assoc Thai 2007;90:2494-8.
16. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
17. Sanna G, Zampino MG, Pelosi G, Nole F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of biphosphonates. Ann Oncol 2005;16:1207-8.
18. Shlomi B, Levy Y, Kleinman S, Better H, Kahn A, Shtabsky Aet al. Avascular necrosis of the jaw bone after bisphosphonate therapy. Harefuah 2005;144:536-9, 600, 599.
19. Thakkar SG, Isada C, Smith J, Karam MA, Reed J, Tomford JWet al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006;23:51-6.
20. Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien KlinWochenschr 2006;118:473-8.
21. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. AmJ Hematol 2006;81:73-5.
22. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
23. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J AmDent Assoc 2005;136:1675-81.
24. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 2005;71:111-13.
25. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 2005;34:613-17.
26. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:135.
27. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65:1321-7.
28. Friedrich RE, Blake FA. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients. Anticancer Res 2007;27:1841-5.
29. Fugazzotto PA, Lightfoot S. Bisphosphonate associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Mass Dent Soc 2006;55:5.
30. Goldman ML, Denduluri N, Berman AW, Sausville R, Guadagnini JP, Kleiner DE et al.A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology 2006;71:306-8.
31. Heras Rincon I, Zubillaga Rodriguez I, Castrillo Tambay M, Montalvo Moreno JJ. Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal 2007;12:E267-71.
32. Kicken M, Van Cann EM, Koole R. Bisphosphonateassociated osteonecrosis of the jaws. 2. Six case reports. Ned Tijdschr Tandheelkd 2007;114: 428-31.
33. Kumar V, Pass B, Guttenberg SA, Ludlow J, Emery RW, TyndallDAet al. Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity. J AmDent Assoc 2007;138:602-9.
34. Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MG, PaulaLMet al. Bisphosphonateassociated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:14-21.
35. Dannemann C, Zwahlen R, Gratz KW. Clinical experiences with bisphopsphonate induced osteochemonecrosis of the jaws. Swiss Med Wkly 2006;136:504-9.
36. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35:588-93.
37. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:115-20.
38. Carneiro E, Vibhute P, Montazem A, Som PM. Bisphosphonate-associated mandibular osteonecrosis. AJNRAmJ Neuroradiol 2006;27:1096-7.
39. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas Get al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.
40. BornsteinMM, Oberli K, Stauffer E, Buser D. Biphosphonate-associated osteonecrosis of the maxilla. Case report and review of the literature. Schweiz Monatsschr Zahnmed 2006;116:1035-47.
41. Braun E, Iacono VJ. Bisphosphonates: case report of nonsurgical periodontal therapy and osteochemonecrosis. Int J Periodontics Restorative Dent 2006;26:315-19.
42. Brooks JK, Gilson AJ, Sindler AJ, Ashman SG, Schwartz KG, Nikitakis NG. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:780-6.
43. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z et al. Bisphosphonaterelated osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008;26:4634-8.
44. Marx RE, Cillo Jr JE, Ulloa JJ. Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410.
45. Treister NS, Richardson P, Schlossman R, Miller K, Woo SB. Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:e1-4.
46. Seehra J, Sloan P, Oliver RJ. Paget's disease of bone and osteonecrosis. Dent Update 2009;36:166-72.
47. Mavrokoski T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23.
48. Wynn RL. Oral bisphosphonates and osteonecrosis of the jaw. Gen Dent 2007;55:8-10.
49. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006;35:801-3.
50. Hoff AO, Toth BB, Altundag K, JohnsonMM, Warneke CL, HuMet al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36.
51. Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007;48:56-64.
52. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, MartinD et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2009; E-pub ahead of print.
53. Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 2008;37:196-200.
54. Pazianas M, Miller P, BlumentalsWA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548-58.
55. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009;112:605-9.
56. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, BalanzateguiAet al. Bisphosphonaterelated osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008;112:2709-12.
57. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9.
58. Cheng A, Mavrokokki A, Carter G, Stein B, Fazzalari NL, Wilson DF et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50:S4-13.
59. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35:1391-7.
60. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J 2009;206:93-8.
61. Affairs ADACoS. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J AmDent Assoc 2006;137:1144-50.
62. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y et al. 'Bis-phossy jaws' - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2008;36: 95-103.
63. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62:489-96.
64. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J AmDent Assoc 2007;138:971-7.
65. CuriMM, Cossolin GS, Koga DH, Araujo SR, Feher O, dos SantosMOet al. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases. J Oral Maxillofac Surg 2007;65: 349-55.
66. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol 2007;33:371-82.
67. Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint SurgAm2007;89:96-101.
68. Wermelin K, Aspenberg P, Linderback P, Tengvall P. Bisphosphonate coating on titanium screws increases mechanical fixation in rat tibia after two weeks. J Biomed Mater Res A 2008;86:220-7.
69. Wermelin K, Suska F, Tengvall P, Thomsen P, Aspenberg P. Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone 2008;42:365-71.
70. Ferguson SJ, Langhoff JD, Voelter K, von Rechenberg B, Scharnweber D, Bierbaum S et al. Biomechanical comparison of different surface modifications for dental implants. Int J Oral Maxillofac Implants 2008;23: 1037-46.
71. Aspenberg P. Bisphosphonates and implants: an overview. Acta Orthop 2009;80:119-23.
72. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21:349-53.
73. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66:223-30.